RT Journal Article
SR Electronic
T1 Epidemiological and immunological features of obesity and SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.11.20229724
DO 10.1101/2020.11.11.20229724
A1 Nilles, Eric J
A1 Siddiqui, Sameed M
A1 Fischinger, Stephanie
A1 Bartsch, Yannic C
A1 de Saint Aubin, Michael
A1 Zhou, Guohai
A1 Gluck, Matthew J
A1 Berger, Samuel
A1 Rhee, Justin
A1 Petersen, Eric
A1 Mormann, Benjamin
A1 Loesche, Michael
A1 Chen, Zhilin
A1 Yu, Jingyou
A1 Gebre, Makda
A1 Atyeo, Caroline
A1 Gorman, Matthew J
A1 Zhu, Alex Lee
A1 Burke, John
A1 Slein, Matthew
A1 Hasdianda, Mohammad A
A1 Jambaulikar, Guruprasad
A1 Boyer, Edward
A1 Sabeti, Pardis
A1 Barouch, Dan H
A1 Julg, Boris D
A1 Kucharski, Adam J
A1 Musk, Elon R
A1 Lauffenburger, Douglas A
A1 Alter, Galit
A1 Menon, Anil S
YR 2020
UL http://medrxiv.org/content/early/2020/12/11/2020.11.11.20229724.abstract
AB Obesity is a key correlate of severe SARS-CoV-2 outcomes while the role of obesity on risk of SARS-CoV-2 infection, symptom phenotype, and immune response are poorly defined. We examined data from a prospective SARS-CoV-2 cohort study to address these questions. Serostatus, body mass index, demographics, comorbidities, and prior COVID-19 compatible symptoms were assessed at baseline and serostatus and symptoms monthly thereafter. SARS-CoV-2 immunoassays included an IgG ELISA targeting the spike RBD, multiarray Luminex targeting 20 viral antigens, pseudovirus neutralization, and T cell ELISPOT assays. Our results from a large prospective SARS-CoV-2 cohort study indicate symptom phenotype is strongly influenced by obesity among younger but not older age groups; we did not identify evidence to suggest obese individuals are at higher risk of SARS-CoV-2 infection; and, remarkably homogenous immune activity across BMI categories suggests natural- and vaccine-induced protection may be similar across these groups.Competing Interest StatementGA is a founder of Seromyx Systems Inc., a company developing platform technology that describes the antibody immune response. GAs interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. PS is a co-founder of, shareholder in, and advisor to Sherlock Biosciences, Inc, as well as a Board member of and shareholder in Danaher Corporation. MJG, SB, YH, JR, EP, BM, ASM and ERM are employees of Space Exploration Technologies Corp. All other authors have declared that no conflict of interest exists.Funding StatementWe acknowledge funding support from Space Exploration Technologies Corporation, the Brigham and Womens Department of Emergency Medicine, the Ragon Institute of MGH, MIT and Harvard, the Massachusetts Consortium on Pathogen Readiness (MassCPR), the NIH (3R37AI080289-11S1), FDA HHSF223201810172C, and the Gates foundation Global Health Vaccine Accelerator Platform funding. EJN is supported by the CDC (U01 GH002238). SMS was partially supported by the US Food and Drug Administration (HHSF223201810172C). DAL was partially supported by the National Institute for Allergy and Infectious Disease (U19 AI135995).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Western Institutional Review Board. The use of de-identified data and biological samples was approved by the Mass General Brigham Healthcare Institutional Review Board. All participants provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author, EJN. The data are not publicly available due to their containing information that could compromise the privacy of research participants.